A 10-week Randomized, Double-blind, Placebo-controlled, Prospective, International, Multicentre, Phase IIa Study of S42909 on Leg Ulcer Healing.
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs S 42909 (Primary)
- Indications Leg ulcer
- Focus Proof of concept; Therapeutic Use
- Sponsors ILKOS THERAPEUTICS
- 15 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2018.
- 15 Aug 2017 Status changed from not yet recruiting to recruiting.
- 15 Mar 2017 New trial record